How we treat bleeding associated with direct oral anticoagulants

Blood Transfusion

Volumn 14, Issue 5, 2016, Pages 465-473

  Marano, Giuseppe ^a   Vaglio, Stefania ^a   Pupella, Simonetta ^a   Liumbruno, Giancarlo M ^a   Franchini, Massimo ^b  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^b CARLO POMA HOSPITAL   (Italy)

Author keywords

Anticoagulation reversal; Bleeding; Direct oral anticoagulants; Fresh frozen plasma; Prothrombin complex concentrates

Indexed keywords

ACTIVATED CARBON; ANTICOAGULANT AGENT; ANTIDOTE; BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 7A; FRESH FROZEN PLASMA; HEMOSTATIC AGENT; PROCOAGULANT; PROTHROMBIN COMPLEX; RECOMBINANT BLOOD CLOTTING FACTOR 7A;

BLEEDING; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; DRUG SAFETY; GASTROINTESTINAL HEMORRHAGE; HEMODIALYSIS; HUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; HEMORRHAGE; ORAL DRUG ADMINISTRATION; STROKE; THROMBOEMBOLISM;

ADMINISTRATION, ORAL; ANTICOAGULANTS; ANTIDOTES; HEMORRHAGE; HUMANS; STROKE; THROMBOEMBOLISM;

EID: 84992052018     PISSN: 17232007     EISSN: None     Source Type: Journal    
DOI: 10.2450/2016.0180-15     Document Type: Review

References (104)

1. Goldhaber SZ, Bounameaux H. Pulmonary embolism and deep vein thrombosis. Lancet 2012;379:1835-46.
2. Mannucci PM, Franchini M. Old and new anticoagulant drugs: a minireview. Ann Med 2011;43:116-23.
3. Franchini M, Liumbruno GM, Bonfanti C, Lippi G. The evolution of anticoagulant therapy. Blood Transfus 2016;14:175-84.
4. Franchini M, Mannucci PM. A new era for anticoagulants. Eur J Intern Med 2009;20:562-8.
5. Franchini M, Mannucci PM. New anticoagulants for treatment of venous thromboembolism. Eur J Intern Med 2012;23:692-5.
6. Ageno W, Gallus AS, Wittkowsky A, et al; American College of Chest Physicians. Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141(2 Suppl):e44S-88S.
7. Weitz JI, Eikelboom JW, Samama MM; American College of Chest Physicians. New antithrombotic drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141(2 Suppl):e120S-51S.
8. Eriksson BI, Dahl OE, Rosencher N, et al. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the REMODEL randomized trial. J Thromb Haemost 2007;5:2178-85.
9. Eriksson BI, Dahl OE, Rosencher N, et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet 2007;370:949-56.
10. Schulman S, Kearon C, Kakkar AK, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009;361:2342-52.
11. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139-51.
12. Lassen MR, Raskob GE, Gallus A, et al. Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N Engl J Med 2009;361:594-604.
13. Lassen MR, Gallus A, Raskob GE, et al. Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. N Engl J Med 2010;363:2487-98.
14. Agnelli G, Buller HR, Cohen A, et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 2013;369:799-808.
15. Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011;365:981-92.
16. Fuji T, Wang CJ, Fujita S, et al. Safety and efficacy of edoxaban, an oral factor Xa inhibitor, versus enoxaparin for thromboprophylaxis after total knee arthroplasty: the STARS E-3 trial. Thromb Res 2014;134:1198-204.
17. Fuji T, Wang CJ, Fujita S, et al. Safety and efficacy of edoxaban, an oral factor Xa inhibitor, for thromboprophylaxis after total hip arthroplasty in Japan and Taiwan. J Arthroplasty 2014;29:2439-46.
18. Hokusai-VTE Investigators; Büller HR, Décousus H, Grosso MA, et al. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med 2013;369:1406-15.
19. Giugliano RP, Ruff CT, Braunwald E, et al; ENGAGE AFTIMI 48 Investigators. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013;369:2093-104.
20. Eriksson BI, Borris LC, Friedman RJ, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 2008;358:2765-75.
21. Lassen MR, Ageno W, Borris LC, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med 2008;358:2776-86.
22. The EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010;363:2499-510.
23. Patel MR, Mahaffey KW, Garg J, et al; ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011;365:883-91.
24. Masotti L, Di Napoli M, Godoy DA, et al. The practical management of intracerebral hemorrhage associated with oral anticoagulant therapy. Int J Stroke 2011;6:228-40.
25. Dzik WS. Reversal of drug-induce anticoagulation: old solutions and new problems. Transfusion 2012;52:45S-55S.
26. Miesbach W, Seifried E. New direct oral anticoagulants - current therapeutic options and treatment recommendations for bleeding complications. Thromb Haemost 2012;108:625-32.
27. Siegal DM, Garcia DA, Crowther MA. How I treat targetspecific oral anticoagulant-associated bleeding. Blood 2014;123:1152-8.
28. Franchini M, Bonfanti C, Mannucci PM. Management of bleeding associated with new oral anticoagulants. Semin Thromb Hemost 2015;41:788-801.
29. Bloom BJ, Filion KB, Atallah R, Eisenberg MJ. Metaanalysis of randomized controlled trials on the risk of bleeding with dabigatran. Am J Cardiol 2014;113:1066-74.
30. Miller CS, Grandi SM, Shimony A, et al. Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation. Am J Cardiol 2012;110:453-60.
31. Dentali F, Riva N, Crowther M, et al. Efficacy and safety of the novel oral anticoagulants in atrial fibrillation: a systematic review and meta-analysis of the literature. Circulation 2012;126:2381-91.
32. Kwong JS, Lam YY, Yan BP, Yu CM. Bleeding of new oral anticoagulants for stroke prevention in atrial fibrillation: a meta-analysis of randomized controlled trials. Cardiovasc Drugs Ther 2013;27:23-35.
33. Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 2014;383:955-62.
34. Fox BD, Kahn SR, Langleben D, et al. Efficacy and safety of novel oral anticoagulants for treatment of acute venous thromboembolism: direct and adjusted indirect meta-analysis of randomised controlled trials. BMJ 2012;345:e7498.
35. van der Hulle T, Kooiman J, den Exter PL, et al. Effectiveness and safety of novel oral anticoagulants as compared with vitamin K antagonists in the treatment of acute symptomatic venous thromboembolism: a systematic review and metaanalysis. J Thromb Haemost 2014;12:320-8.
36. Chai-Adisaksopha C, Crowther M, Isayama T, Lim W. The impact of bleeding complications in patients receiving target-specific oral anticoagulants: a systematic review and meta-analysis. Blood 2014;124:2450-8.
37. Camm AJ, Lip GY, De Caterina R, et al.; ESC Committee for Practice Guidelines (CPG). 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 2012;33:2719-47.
38. Franchini M, Velati C. The use of novel oral anticoagulants: the debate continues! Blood Transfus 2015;13:170-1.
39. Riva N, Ageno W. Which patients with venous thromboembolism should receive non-vitamin K antagonist oral anticoagulants? The majority. Blood Transfus 2015;13:181-3.
40. Prandoni P. The treatment of venous thromboembolism with novel oral anticoagulants: warnings and limitations. Blood Transfus 2015;13:178-80.
41. Larsen TB, Rasmussen LH, Skjøth F, et al. Efficacy and safety of dabigatran etexilate and warfarin in "real-world" patients with atrial fibrillation: a prospective nationwide cohort study. J Am Coll Cardiol 2013;61:2264-73.
42. Graham DJ, Reichman ME, Wernecke M, et al. Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for non-valvular atrial fibrillation. Circulation 2015;131:157-64.
43. Chang HY, Zhou M, Tang W, et al. Risk of gastrointestinal bleeding associated with oral anticoagulants: population based retrospective cohort study. BMJ 2015;350:h1585.
44. Abraham NS, Singh S, Alexander GC, et al. Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort study. BMJ 2015;350:h1857.
45. Beyer-Westendorf J, Förster K, Pannach S, et al. Rates, management, and outcome of rivaroxaban bleeding in daily care: results from the Dresden NOAC registry. Blood 2014;124:955-62.
46. Beyer-Westendorf J. Pattern and management of bleeding complications with new oral anticoagulants. Results of the prospective Dresden NOAC Registry (NCT01588119) [Abstract]. J Thromb Haemost 2013;11:774.
47. Fenger-Eriksen C, Münster AM, Grove EL. New oral anticoagulants: clinical indications, monitoring and treatment of acute bleeding complications. Acta Anaesthesiol Scand 2014;58:651-9.
48. Liew A, Eikelboom JW, O'Donnell M, Hart RG. Assessment of anticoagulation intensity and management of bleeding with old and new oral anticoagulants. Can J Cardiol 2013;29:S34-44.
49. Siegal DM, Cuker A. Reversal of novel oral anticoagulants in patients with major bleeding. J Thromb Thrombolysis 2013;35:391-8.
50. Liumbruno G, Bennardello F, Lattanzio A, et al. Recommendations for the transfusion of plasma and platelets. Blood Transfus 2009;7:132-50.
51. Liumbruno G, Bennardello F, Lattanzio A, et al. Recommendations for the use of antithrombin concentrates and prothrombin complex concentrates. Blood Transfus 2009;7:325-34.
52. Liumbruno GM, Bennardello F, Lattanzio A, et al. Recommendations for the transfusion management of patients in the peri-operative period. I. The pre-operative period. Blood Transfus 2011;9:19-40.
53. Franchini M, Liumbruno GM, Lanzoni M, et al. Clinical use and the Italian demand for prothrombin complex concentrates. Blood Transfus 2013;11(4 Suppl):s94-100.
54. Enriquez A, Lip GY, Baranchuk A. Anticoagulation reversal in the era of the non-vitamin K oral anticoagulants. EP Europace 2015; euv030.
55. Mo Y, Yam FK. Recent advances in the development of specific antidotes for target-specific oral anticoagulants. Pharmacotherapy 2015;35:198-207.
56. PRADAXA (dabigatran etexilate mesylate) capsules for oral use [package insert]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals Inc.; 2013. Available at: http://bidocs. boehringeringelheim.com/BIWebAccess/ViewServlet. ser?docBase=renetnt&folderPath=/Prescribing%20 Information/PIs/Pradaxa/Pradaxa.pdf. Accessed on 08/07/2015.
57. Stangier J, Rathgen K, Stähle H, Mazur D. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study. Clin Pharmacokinet 2010;49:259-68.
58. Xarelto (rivaroxaban) prescribing information. Titusville, NJ: Janssen Pharmaceuticals, Inc. Available at: www.xareltohcp. com/sites/default/files/pdf/xarelto-0.pdf#zoom=100. Accessed on 08/07/2015.
59. Eliquis (apixaban) prescribing information. Princeton, NJ: Bristol-Myers Squibb Company. Available at: http://packageinserts.bms.com/pi/pi-eliquis.pdf. Accessed on 08/07/2015.
60. van Ryn J, Sieger P, Kink-Eiband M, et al. Adsorption of dabigatran etexilate in water or dabigatran in pooled human plasma by activated charcoal in vitro [Abstract]. 51st ASH Annual Meeting and Exposition 2009; n. 1065.
61. Gehrie E, Tormey C. Novel oral anticoagulants: efficacy, laboratory measurement, and approaches to emergent reversal. Arch Pathol Lab Med 2015;139:687-92.
62. Franchini M, Lippi G. Prothrombin complex concentrates: and update. Blood Transfus 2010;40:812-24.
63. Dickneite G, Hoffman M. Reversing the new oral anticoagulants with prothrombin complex concentrates (PCCs): what is the evidence. Thromb Haemost 2014;11:189-98.
64. Zhou W, Schwarting S, Illanes S, et al. Hemostatic therapy in experimental intracerebral hemorrhage associated with the direct thrombin inhibitor dabigatran. Stroke 2011;42:3594-9.
65. Pragst I, Zeitler SH, Doerr B, et al. Reversal of dabigatran anticoagulation by prothrombin complex concentrate (Beriplex P/N) in a rabbit model. J Thromb Haemost 2012;10:1841-8.
66. van Ryn J, Kink-Eiband M, Clemens A. The successful reversal of dabigatran-induced bleeding by coagulation factor concentrates in a rat tail bleeding model do not correlate with ex vivo markers of anticoagulation [Abstract]. Blood 2011;118:2316.
67. Herzog E, Kaspereit F, Krege W, et al. Non-clinical safety and efficacy of prothrombin complex concentrates (PCC) for the reversal of dabigatran mediated anticoagulation [Abstract]. J Thromb Haemost 2013;11(Suppl 2):693.
68. Godier A, Miclot A, Le Bonniec B, et al. Evaluation of prothrombin complex concentrate and recombinant activated factor VII to reverse rivaroxaban in a rabbit model. Anesthesiology 2012;116:94-102.
69. Dinkelaar J, Molenaar PJ, Ninivaggi M, et al. In vitro assessment, using thrombin generation, of the applicability of prothrombin complex concentrate as an antidote for Rivaroxaban. J Thromb Haemost 2013;11:1111-8.
70. Körber MK, Langer E, Ziemer S, et al. Measurement and reversal of prophylactic and therapeutic peak levels of rivaroxaban: an in vitro study. Clin Appl Thromb Hemost 2014;20:735-40.
71. Eerenberg ES, Kamphuisen PW, Sijpkens MK, et al. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation 2011;124:1573-9.
72. Escolar G, Fernandez-Gallego V, Arellano-Rodrigo E, et al. Reversal of apixaban induced alterations in hemostasis by different coagulation factor concentrates: significance of studies in vitro with circulating human blood. PLoS One 2013;8:e78696.
73. Levi M, Moore KT, Castillejos CF, et al. Comparison of threefactor and four-factor prothrombin complex concentrates regarding reversal of the anticoagulant effects of rivaroxaban in healthy volunteers. J Thromb Haemost 2014;12:1428-36.
74. Brown KS, Wickremasingha P, Parasrampuria DA, et al. The impact of prothrombin complex concentrate on the coagulopathy effects of edoxaban. JACC 2014;63:A2095.
75. Galan AM, Arellano-Rodrigo E, Sanz V, et al. Effects of rivaroxaban and dabigatran on hemostasis and reversion of their antithrombotic effects by different coagulation factors: evidence raised from a clinical study in healthy volunteers [Abstract]. J Thromb Haemost 2013;11(Suppl 2):418.
76. Arellano-Rodrigo E, Galan AM, Sanz V, et al. Alterations induced by rivaroxaban on hemostasis can be reversed by different coagulation factor concentrates: in vitro experimental studies with steady and circulating human blood [Abstract]. J Thromb Haemost 2013;11(Suppl 2):953.
77. Perzborn E, Gruber A, Tinel H, et al. Reversal of rivaroxaban anticoagulation by haemostatic agents in rats and primates. Thromb Haemost 2013;110:162-72.
78. Chan HHW, Atkinson HM, Goncharenko M, et al. Reversal of dabigatran using recombinant activated factor VII and activated prothrombin complex concentrates in thromboelastography assay. J Thromb Haemost 2011;9:576-7.
79. Marlu R, Hodaj E, Paris A, et al. Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomised crossover ex vivo study in healthy volunteers. Thromb Haemost 2012;108:217-24.
80. Khoo TL W C, Kershaw G, Reddel CJ, et al. The use of FEIBA in the correction of coagulation abnormalities induce by dabigatran. Int J Lab Hem 2013;35:222-4.
81. Herrmann R, Thom J, Wood A, et al. Thrombin generation using the calibrated automated thrombinoscope to assess reversibility of dabigatran and rivaroxaban. Thromb Haemost 2014;111:989-95.
82. Martin AC, Gouin-Thibault I, Siguret V, et al. Multimodal assessment of non-specific hemostatic agents for apixaban reversal. J Thromb Haemost 2015;13:426-36.
83. Lambourne MD, Eltringham-Smith LJ, Gataiance S, et al. Prothrombin complex concentrates reduce blood loss in murine coagulopathy induced by warfarin, but not in that induced by dabigatran etexilate. J Thromb Haemost 2012;10:1830-40.
84. Fukuda T, Honda Y, Kamisato C, et al. Reversal of anticoagulant effects of edoxaban, an oral, direct factor Xa inhibitor, with haemostatic agents. Thromb Haemost 2012;107:253-9.
85. Lee FMH, Chan AKC, Lau KK, Chan HH. Reversal of new, factor-specific oral anticoagulants by rFVIIa, prothrombin complex concentrate and activated protrhombin complex concentrate: a review of animal and human studies. Thromb Res 2014;133:705-13.
86. Schiele F, van Ryn J, Canada K, et al. A specific antidote for dabigatran: functional and structural characterization. Blood 2013;121:3554-62.
87. Glund S, Stangier J, Schmohl M, et al. A specific antidote for dabigatran: immediate, complete and sustained reversal of dabigatran induced anticoagulation in healthy male volunteers [Abstract]. Circulation 2013;128:A17765.
88. Glund S, Stangier J, Schmohl M, et al. Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, double-blind phase 1 trial. Lancet 2015;386:680-90.
89. Pollack CV Jr, Reilly PA, Eikelboom J, et al. Idarucizumab for dabigatran reversal. N Engl J Med 2015;373:511-20.
90. Glund S, Stangier J, Schmohl M, et al. Idarucizumab, a specific antidote for dabigatran: immediate, complete and sustained reversal of dabigatran induced anticoagulation in elderly and renally impaired subjects [abstract]. Blood 2014;124:344.
91. Glund S, Moschetti V, Norris S, et al. A randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran. Thromb Haemost 2015;113:943-51.
92. Greinacher A, Thiele T, Selleng K. Reversal of anticoagulants: an overview of current developments. Thromb Haemost 2015;113:931-42.
93. Sheffield WP, Lambourne MD, Eltringham-Smith LJ, et al. γT-S195A thrombin reduces the anticoagulant effects of dabigatran in vitro and in vivo. J Thromb Haemost 2014;12:1110-5.
94. Lu G, DeGuzman FR, Hollenbach SJ, et al. A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa. Nat Med 2013;19:446-51.
95. Crowther MA, Kitt M, McClure M, et al. Randomized, double-blind, placebo-controlled single ascending dose pharmacokinetic and pharmacodynamic study of PRT064445, a universal antidote for factor Xa inhibitors [Abstract]. Arterioscler Thromb Vasc Biol 2013;33:A10.
96. Crowther MA, Kitt M, Lorenz T, et al. A phase 2 randomized, double-blind, placebo-controlled trial of PRT064445, a novel, universal antidote for direct and indirect factor Xa inhibitors [Abstract]. J Thromb Haemost 2013;11(Suppl):AS20.1.
97. Crowther MA, Mathur V, Kitt M, et al. A phase 2 randomized, double-blind, placebo-controlled trial demonstrating reversal of rivaroxaban induced anticoagulation in healthy subjects by andexanet alfa (PRT064445), an antidote for FXa inhibitors [Abstract]. Blood 2013;122:A3636.
98. ™-A: A phase 3 randomized, double-blind, placebo-controlled trial, demonstrating reversal of apixaban-induced anticoagulation in older subjects by andexanet alfa (PRT064445), a universal antidote for factor Xa (FXa) inhibitors [Abstract]. Circulation 2014;130:2116.
99. ™-A PART 2: A phase 3 randomized, double-blind, placebo-controlled trial, demonstrating sustained reversal of apixabaninduced anticoagulation in older subjects by andexanet alfa (PRT064445), a universal antidote for factor Xa (FXa) inhibitors [Abstract]. J Thromb Haemost 2015;13(Suppl 2):84.
100. Recombinant Factor Xa Inhibitor Antidote. ClinicalTrials. gov. NCT02329327. Available at: https://clinicaltrials.gov/ct2/show/NCT02329327. Accessed on 08/07/2015.
101. Laulicht B, Bakhru S, Lee C, et al. Small molecule antidote for anticoagulants [Abstract]. Circulation 2012;126:10021.
102. Effects of a Double-Blind, Single Dose of PER977 Administered Alone, and Following a Single Dose of Edoxaban (PER977-P1). ClinicalTrials.gov. NCT01826266. Available at: https://clinicaltrials.gov/ct2/show/NCT01826266. Last accessed on 08/07/2015.
103. Study of PER977 Administered to Subjects With Steady State Edoxaban Dosing and Re-anticoagulation With Edoxaban. ClinicalTrials.gov. NCT02207257. Available at: https://clinicaltrials.gov/ct2/show/NCT02207257. Last accessed on 08/07/2015.
104. Ansell JE, Bakhru SH, Laulicht BE, et al. Use of PER977 to reverse the anticoagulant effect of edoxaban [Letter]. N Engl J Med 2014;371:2141-2.